According to TipRanks.com, Wilbur is a 1-star analyst with an average return of -1.6% and a 45.9% success rate. Wilbur covers the Healthcare sector, focusing on stocks such as Amphastar Pharmaceuticals, Amneal Pharmaceuticals, and Flexion Therapeutics.
Currently, the analyst consensus on Perrigo Company is a Hold with an average price target of $50.33, which is a 13.4% upside from current levels. In a report issued on January 6, RBC Capital also downgraded the stock to Hold with a $49.00 price target.
Based on Perrigo Company’s latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of $1.21 billion and GAAP net loss of $155 million. In comparison, last year the company earned revenue of $1.19 billion and had a net profit of $92.2 million.
Based on the recent corporate insider activity of 43 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of PRGO in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Perrigo Co. Plc is a healthcare company, which engages in the production of over-the-counter consumer goods and specialty pharmaceutical products. It operates through the following segments: Consumer Healthcare Americas, Consumer Healthcare International, and Prescription Pharmaceuticals. The Consumer Healthcare Americas segment comprises the U.S., Mexico and Canada consumer healthcare business. The Consumer Healthcare International segment includes branded consumer healthcare business primarily in Europe and consumer focused businesses in the U.K., Australia, and Israel. The Prescription Pharmaceuticals refers to the U.S. prescription pharmaceuticals business. The company was founded by Luther Perrigo in 1887 and is headquartered in Dublin, Ireland.